Periprocedural heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysis

Jing Wen Yong, Li Xia Yang, Bright Eric Ohene, Yu Jie Zhou, Zhi Jian Wang, Jing Wen Yong, Li Xia Yang, Bright Eric Ohene, Yu Jie Zhou, Zhi Jian Wang

Abstract

Background: Periprocedural heparin bridging therapy aims to reduce the risk of thromboembolic events in patients requiring an interruption in their anticoagulation therapy for the purpose of an elective procedure. The efficacy and safety of heparin bridging therapy has not been well established.

Objectives: To compare through meta-analysis the effects of heparin bridging therapy on the risk of major bleeding and thromboembolic events of clinical significance among patients taking oral anticoagulants.

Methods: We searched PubMed, EMBASE and the Cochrane library from January 2005 to July 2016. Studies were included if they reported clinical outcomes of patients receiving heparin bridging therapy during interruption of oral anticoagulant for operations. Data were pooled using random-effects modeling.

Results: A total of 25 studies, including 6 randomized controlled trials and 19 observational studies, were finally included in this analysis. Among all the 35,944 patients, 10,313 patients were assigned as heparin bridging group, and the other 25,631 patients were non-heparin bridging group. Overall, compared with patients without bridging therapy, heparin bridging therapy increased the risk of major bleeding (OR = 3.23, 95%CI: 2.06-5.05), minor bleeding (OR = 1.52, 95%CI: 1.06-2.18) and overall bleeding (OR = 2.83, 95%CI: 1.86-4.30).While there was no significant difference in thromboembolic events (OR = 0.99,95%CI: 0.49-2.00), stroke or transient ischemic attack(OR = 1.45, 95%CI: 0.93-2.26,) or all-cause mortality (OR = 0.71, 95%CI: 0.31-1.65).

Conclusions: Heparin-bridging therapy increased the risk of major and minor bleeding without decreasing the risk of thromboembolic events and all cause death compared to non-heparin bridging.

Keywords: Anticoagulation; Bridging; Heparin; Meta-analysis.

Conflict of interest statement

Ethics approval and consent to participate

(Not applicable)

Consent for publication

(Not Applicable)

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow chart of study selection
Fig. 2
Fig. 2
Forest plot of major bleeding for heparin-bridging and non-heparin bridging regiments
Fig. 3
Fig. 3
Forest plot of overall bleeding for heparin-bridging and non-heparin bridging regiments
Fig. 4
Fig. 4
Forest plot of thromboembolism for heparin-bridging and non-heparin bridging regiments
Fig. 5
Fig. 5
Forest plot of all cause death for heparin-bridging and non-heparin bridging regiments
Fig. 6
Fig. 6
Funnel plots of major bleeding (a) and thromboembolism (b) for heparin-bridging and non-heparin bridging regiments

References

    1. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative Management of Antithrombotic Therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S. doi: 10.1378/chest.11-2298.
    1. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084–2093. doi: 10.1056/NEJMoa1302946.
    1. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–1639. doi: 10.1161/CIRCULATIONAHA.112.105221.
    1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–2104. doi: 10.1161/CIR.0000000000000040.
    1. Stroup DF. Meta-analysis of observational observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE). Group. 2000;
    1. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e576S–e600S. doi: 10.1378/chest.11-2305.
    1. Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, Kowey PR, Mahaffey KW, Sherwood MW, Chang P, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) Circulation. 2015;131(5):488–494. doi: 10.1161/CIRCULATIONAHA.114.011777.
    1. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–833. doi: 10.1056/NEJMoa1501035.
    1. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163(20):2532–2533.
    1. Varkarakis IM, Rais-Bahrami S, Allaf ME, Lima GC, Permpongkosol S, Rao P, Jarrett TW, Kavoussi LR. Laparoscopic renal-adrenal surgery in patients on oral anticoagulant therapy. J Urol. 2005;174(3):1020–1023. doi: 10.1097/01.ju.0000169461.35421.f6.
    1. Marquie C, De Geeter G, Klug D, Kouakam C, Brigadeau F, Jabourek O, Trillot N, Lacroix D, Kacet S. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European society of Cardiology. 2006;8(4):283–287. doi: 10.1093/europace/eul011.
    1. Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008;83(6):639–645. doi: 10.1016/S0025-6196(11)60891-4.
    1. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168(1):63–69. doi: 10.1001/archinternmed.2007.23.
    1. Karjalainen P, Porela P, Ylitalo A, Vikman S, Kai N, Vaittinen MA, Airaksinen T, Niemelä M, Puurunen M, Airaksinen J. Safety of percutaneous coronary intervention during uninterrupted anticoagulant treatment. Eur Heart J. 2008;29(8):1001. doi: 10.1093/eurheartj/ehn099.
    1. Daniels PR, McBane RD, Litin SC, Ward SA, Hodge DO, Dowling NF, Heit JA. Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res. 2009;124(3):300–305. doi: 10.1016/j.thromres.2009.01.011.
    1. Robinson M, Healey JS, Eikelboom J, Schulman S, Morillo CA, Nair GM, Baranchuk A, Ribas S, Evans G, Connolly SJ, et al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing and clinical electrophysiology: PACE. 2009;32(3):378–382. doi: 10.1111/j.1540-8159.2008.02247.x.
    1. Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin. Am Heart J. 2009;158(2):252–256. doi: 10.1016/j.ahj.2009.06.005.
    1. Billett HH, Scorziello BA, Giannattasio ER, Cohen HW. Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit? J Thromb Thrombolysis. 2010;30(4):479–485. doi: 10.1007/s11239-010-0470-8.
    1. Ercan M, Bostanci EB, Ozer I, Ulas M, Ozogul YB, Teke Z, Akoglu M. Postoperative hemorrhagic complications after elective laparoscopic cholecystectomy in patients receiving long-term anticoagulant therapy. Langenbeck’s archives of surgery / Deutsche Gesellschaft fur Chirurgie. 2010;395(3):247–253. doi: 10.1007/s00423-009-0483-y.
    1. Ghanbari H, Feldman D, Schmidt M, Ottino J, Machado C, Akoum N, Wall TS, Daccarett M. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing and clinical electrophysiology : PACE. 2010;33(4):400–406. doi: 10.1111/j.1540-8159.2010.02703.x.
    1. Jaffer AK, Brotman DJ, Bash LD, Mahmood SK, Lott B, White RH. Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med. 2010;123(2):141–150. doi: 10.1016/j.amjmed.2009.09.017.
    1. McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30(3):442–448. doi: 10.1161/ATVBAHA.109.199406.
    1. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, et al. Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol. 2010;55(21):2376–2382. doi: 10.1016/j.jacc.2009.12.056.
    1. Smoyer-Tomic K, Siu K, Walker DR, Johnson BH, Smith DM, Sander S, Amin A. Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation. American journal of cardiovascular drugs: drugs, devices, and other. interventions. 2012;12(6):403–413.
    1. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343–348. doi: 10.1161/CIRCULATIONAHA.111.090464.
    1. Lahtela H, Rubboli A, Schlitt A, Karjalainen PP, Niemelä M, Vikman S, Puurunen M, Weber M, Valencia J, Biancari F. Heparin bridging vs. uninterrupted oral anticoagulation in patients with atrial fibrillation undergoing coronary artery stenting. Results from the AFCAS registry. Circulation journal official journal of the Japanese circulation Society. 2012;76(6):1363. doi: 10.1253/circj.CJ-11-1206.
    1. Schulman S, Healey JS, Douketis JD, Delaney J, Morillo CA. Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial. Thromb Res. 2014;134(4):814–818. doi: 10.1016/j.thromres.2014.07.028.
    1. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35(28):1888–1896. doi: 10.1093/eurheartj/eht557.
    1. Kim TH, Kim JY, Mun HS, Lee HY, Roh YH, Uhm JS, Pak HN, Lee MH, Joung B. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. Journal of thrombosis and haemostasis: JTH. 2015;13(2):182–190. doi: 10.1111/jth.12810.
    1. Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113(3):625–632. doi: 10.1160/TH14-04-0305.
    1. Dewilde WJ, Janssen PW, Kelder JC, Verheugt FW, De Smet BJ, Adriaenssens T, Vrolix M, Brueren GB, Van MC, Cornelis K. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. Eurointervention journal of Europcr in collaboration with the working group on interventional cardiology of the European society of Cardiology. 2015;11(4):381. doi: 10.4244/EIJY14M06_07.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다